Status: Not yet recruiting
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Participants needed: 82
Trial details
Phase: Phase 1, Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Dr David Hasan, M.D.Updated: Mar 25, 2026Locations: 2
Eligibility criteria
Age 18-85 [+21]